Reports confirm that the popular weight-loss drug Ozempic, or semaglutide, has shown promise in slowing the aging process in healthy mice, leading to improved memory, muscle function, and overall longevity. The news, released this morning, immediately sent shares of pharmaceutical companies and elite concierge health services skyrocketing, as the planet's wealthiest individuals began preemptively cornering the global supply, ensuring their continued reign on Earth for several decades to come. Investment firms specializing in 'Human Capital Maximization' are already advising clients to consider Ozempic as a mandatory component of any serious long-term financial portfolio.
"We knew it helped you lose ten pounds, but who knew it was also a monthly subscription to thirty more years of ignoring emails?" commented Biffington Sterling IV, CEO of 'EverLast Capital' and a man whose skin currently resembles a freshly glazed donut, despite being a spry 97. "This isn't just about looking good; it's about extending your prime earning years. Why retire when you can simply... not age and keep making those quarterly reports?" Sterling's hedge fund has reportedly purchased 80% of all future semaglutide production for the next fiscal quarter, citing "strategic longevity investments" crucial for maintaining market dominance. Critics quickly pointed out this left little for, well, anyone else.
Economists predict a swift and brutal re-evaluation of the "average lifespan," with new job postings for entry-level positions now including "must be actively pursuing Ozempic-assisted immortality" as a preferred qualification. Experts fear a new "longevity gap" will emerge, where the financially disadvantaged face not only shorter lives but also the unbearable indignity of working for the same ancient bosses for another fifty years. "It's like getting stuck in a very long meeting with someone who has clearly seen too much but refuses to leave the room," noted one anonymous junior associate, who recently turned 27 and is already feeling the pressure to "invest in their future lifespan."
Meanwhile, social media influencers, previously documenting their weight loss journeys, have swiftly pivoted to chronicling their "youth maintenance" routines, showcasing refrigerated drawers full of pre-filled Ozempic pens alongside their bespoke colostrum, red light therapy devices, and personal cryo-chambers. Doctors report a significant uptick in patient requests, primarily from individuals demanding "the one that makes me live forever and still fit into my skinny jeans," with insurance companies quietly updating policies to exclude "any treatments solely for the purpose of avoiding the natural and humbling end to your exploitable existence." One harried GP, Dr. Anya Sharma, lamented, "Patients aren't asking for better health anymore; they're asking for more *time*. Time to earn, time to consume, time to outlive their leases."
The future is clear: those who can afford it will now not only live better but live longer, ensuring a steady supply of eternally youthful-looking executives to oversee the slow decline of everyone else. Turns out, you can buy time, you just have to be able to afford the monthly subscription fee for existence itself, with early bird discounts for venture capitalists.
